Eprosartan
Angiotensin 2 Receptor Blocker — CARDIOVASCULAR SYSTEM
Also known as: eprosartan mesilate, eprosartan mesylate, SKF-108566
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Eprosartan is an ofm drug in the Angiotensin 2 Receptor Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Angiotensin 2 Receptor Antagonists. DrugCentral lists 5 molecular targets, including Agtr1b, Agtr2 and Agtr1|Agtr1b. Recorded indications include Hypertensive disorder.
- Approval status: ofm (first approved 1997 by the FDA).
- Drug class: Angiotensin 2 Receptor Blocker.
- Mechanism of action: Angiotensin 2 Receptor Antagonists.
- Molecular targets: Agtr1b, Agtr2, Agtr1|Agtr1b and Agtr1|Agtr1b|Agtr2 (5 listed in DrugCentral).
- Indications: Hypertensive disorder.
- ATC code: C09CA02 (Angiotensin II receptor blockers (ARBs), plain).
- Molecular formula: C23H24N2O4S; molecular weight 424.52 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hypertensive disorder
Off-label uses (5)
- Atrial fibrillation
- Chronic heart failure
- Diabetic renal disease
- Diastolic heart failure
- Nondiabetic Proteinuric Nephropathy
Contraindications (24)
- Acute pancreatitis
- Anuria
- Azotemia
- Dehydration
- Diabetes mellitus
- Gout
- Hepatic coma
- Hypercalcemia
- Hypercholesterolemia
- Hyperkalemia
- Hyperparathyroidism
- Hyperuricemia
- Hypochloremic alkalosis
- Hypokalemia
- Hypomagnesemia
- Hyponatremia
- Hypovolemia
- Low blood pressure
- Neonatal hyperbilirubinemia
- Pregnancy, function
- Renal artery stenosis
- Secondary angle-closure glaucoma
- Sympathectomy
- Systemic lupus erythematosus
Mechanism & targets
| Mechanism of action (MoA) | Angiotensin 2 Receptor Antagonists |
|---|---|
| Established pharmacologic class | Angiotensin 2 Receptor Blocker |
Molecular targets (5)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Type-1B angiotensin II receptor | Agtr1b | unknown | IC50 9.00 |
| Type-2 angiotensin II receptor | Agtr2 | unknown | IC50 9.00 |
| Angiotensin II receptor (AT-1) type-1 | Agtr1|Agtr1b | unknown | IC50 9.00 |
| Angiotensin II receptor | Agtr1|Agtr1b|Agtr2 | unknown | IC50 9.00 |
| Type-1 angiotensin II receptor | AGTR1 | antagonist | IC50 8.70 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1997-12-22 | FDA | — | ABBVIE |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C09CA02 | CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN › Angiotensin II receptor blockers (ARBs), plain |
C09DA02 | CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS › Angiotensin II receptor blockers (ARBs) and diuretics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Splenic rupture | 38.3 |
| Splenic haemorrhage | 31.9 |
| Toxic skin eruption | 31.8 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Eprosartan is on its molecule page.
| Molecular formula | C23H24N2O4S |
|---|---|
| Molecular weight | 424.52 g/mol |
| CAS number | 133040-01-4 |
| InChIKey | OROAFUQRIXKEMV-LDADJPATSA-N |
| PubChem CID | 5281037 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Eprosartan used for?
DrugCentral lists the following indications for Eprosartan: Hypertensive disorder.
How does Eprosartan work?
Eprosartan is classified as Angiotensin 2 Receptor Antagonists; its molecular targets in DrugCentral include Agtr1b, Agtr2, Agtr1|Agtr1b and Agtr1|Agtr1b|Agtr2.
When was Eprosartan first approved?
Eprosartan was first approved by the FDA in 1997.
What drug class does Eprosartan belong to?
Eprosartan is in the Angiotensin 2 Receptor Blocker class.
What is the chemical formula of Eprosartan?
Eprosartan has the molecular formula C23H24N2O4S and a molecular weight of 424.52 g/mol.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1037 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200987 — compound record and bioactivity
- PubChem CID 5281037 — chemical identifiers
- DrugBank DB00876 — drug record
- FDA UNII 2KH13Z0S0Y — substance identity
- DailyMed: FDA labels for Eprosartan — current prescribing information (label search)
- UniProt P30556 (AGTR1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.